Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) Oct 3, 2023 04:00PM
Cytokinetics Announces Upcoming Presentations at the 2023 HCMS Scientific Sessions and the HFSA Annual Scientific Meeting Oct 2, 2023 04:00PM
Cytokinetics Announces Call for Proposals for Its Sixth Annual Communications Grant Program Sep 28, 2023 07:30AM
Cytokinetics to Participate in Upcoming Investor Conferences Sep 7, 2023 04:00PM
Cytokinetics Announces Start of ACACIA-HCM, a Pivotal Phase 3 Clinical Trial of Aficamten in Patients With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy Sep 6, 2023 07:30AM
View Older Stories

Sep 1, 2023 04:00PM Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 3, 2023 04:00PM Cytokinetics Reports Second Quarter 2023 Financial Results
Aug 1, 2023 04:00PM Cytokinetics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)
Jul 27, 2023 04:00PM Cytokinetics to Announce Second Quarter Results on August 3, 2023
Jul 5, 2023 04:00PM Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jun 20, 2023 07:30AM Cytokinetics Announces Start of MAPLE-HCM, a Phase 3 Clinical Trial of Aficamten Compared to Metoprolol in Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Jun 2, 2023 04:00PM Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Jun 1, 2023 04:00PM Cytokinetics to Participate in Upcoming Investor Conferences
May 20, 2023 10:30AM Cytokinetics Presents New Data in Patients With Non-Obstructive HCM From Cohort 4 of REDWOOD-HCM in Late-Breaking Clinical Trial Session at The European Society of Cardiology Heart Failure 2023 Congre
May 15, 2023 04:00PM Cytokinetics Announces Three Upcoming Presentations at the European Society of Cardiology Heart Failure 2023 Congress
May 11, 2023 07:31AM Cytokinetics (CYTK) Initiates Phase 1 Clinical Study of CK-4021586
May 11, 2023 07:30AM Cytokinetics Announces Initiation of Phase 1 Clinical Study of CK-4021586
May 8, 2023 04:00PM Cytokinetics to Participate in the JMP Securities Life Sciences Conference
May 4, 2023 04:00PM Cytokinetics Reports First Quarter 2023 Financial Results
May 3, 2023 04:00PM Cytokinetics to Hold Annual Meeting of Stockholders
May 1, 2023 04:00PM Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Apr 20, 2023 04:00PM Cytokinetics to Announce First Quarter Results on May 4, 2023
Apr 10, 2023 04:00PM Cytokinetics To Participate In The 22nd Annual Needham Virtual Healthcare Conference
Apr 3, 2023 04:00PM Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mar 31, 2023 07:43AM Cytokinetics (CYTK) Announces COURAGE-ALS Met Criteria for Futility at Second Interim Analysis
Mar 31, 2023 07:30AM Cytokinetics Announces COURAGE-ALS Met Criteria for Futility at Second Interim Analysis
Mar 27, 2023 07:30AM Cytokinetics Releases Inaugural Corporate Responsibility Report
Mar 6, 2023 04:00PM Cytokinetics to Participate in Upcoming Investor Conferences
Mar 6, 2023 05:53AM Cytokinetics (CYTK) Reports Positive Data from Cohort 4 of REDWOOD-HCM and Long-Term Results From FOREST-HCM
Mar 4, 2023 10:00AM Cytokinetics Presents Positive Results From Cohort 4 of REDWOOD-HCM and Long-Term Results From FOREST-HCM at the American College of Cardiology 72nd Annual Scientific Session
Mar 2, 2023 04:00PM Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mar 1, 2023 04:00PM Cytokinetics Reports Fourth Quarter 2022 Financial Results
Mar 1, 2023 05:49AM Cytokinetics (CYTK) Receives CRL from FDA for Omecamtiv Mecarbil
Feb 28, 2023 05:31PM Cytokinetics Receives Complete Response Letter From FDA for New Drug Application for Omecamtiv Mecarbil
Feb 24, 2023 04:00PM Cytokinetics Announces Three Upcoming Presentations at the American College of Cardiology 72nd Annual Scientific Session
Feb 22, 2023 07:30AM Cytokinetics Joins Global Initiative to Recognize International Rare Disease Day
Feb 15, 2023 04:00PM Cytokinetics to Announce Fourth Quarter Results on March 1, 2023
Feb 1, 2023 04:00PM Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jan 30, 2023 07:30AM Cytokinetics Announces Recipients of Its Fifth Annual Communications Grant Program
Jan 4, 2023 04:00PM Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jan 3, 2023 04:00PM Cytokinetics to Participate in the 41st Annual J.P. Morgan Healthcare Conference
Dec 13, 2022 05:45PM Cytokinetics Announces Outcome of FDA Advisory Committee Vote On Omecamtiv Mecarbil
Dec 13, 2022 07:04AM Cytokinetics (CYTK) Stock Trading Halted Today Due to FDA Meeting to Review NDA for Omecamtiv Mecarbil
Dec 13, 2022 07:02AM Cytokinetics Stock Trading Halted Today
Dec 9, 2022 09:03AM Cytokinetics (CYTK) Announces Availability of Briefing Documents for FDA Advisory Committee Meeting on Omecamtiv Mecarbil
Dec 9, 2022 08:59AM Cytokinetics Announces Availability of Briefing Documents for FDA Advisory Committee Meeting on Omecamtiv Mecarbil
Dec 8, 2022 07:30AM Cytokinetics Presents Data at the Virtual 33rd International Symposium on ALS/MND
Dec 7, 2022 07:30AM Cytokinetics Announces Initiation of Phase 1 Clinical Study of CK-3828136
Dec 1, 2022 04:00PM Cytokinetics Announces Presentation at the Virtual 33rd International Symposium on ALS/MND
Nov 7, 2022 07:30AM Cytokinetics Presents New Data at the American Heart Association Scientific Sessions 2022
Nov 3, 2022 04:00PM Cytokinetics Reports Third Quarter 2022 Financial Results
Oct 31, 2022 07:30AM Cytokinetics Announces Three Upcoming Presentations at the American Heart Association Scientific Sessions 2022
Oct 20, 2022 04:00PM Cytokinetics to Announce Third Quarter Results on November 3, 2022
Oct 10, 2022 07:30AM Cytokinetics (CYTK) Announces Continuation of COURAGE-ALS Following First Interim Analysis
Oct 10, 2022 07:30AM Cytokinetics Announces Continuation of COURAGE-ALS Following First Interim Analysis
View Older Stories